| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 49.6 | 33.9 | 49.5 |
| Other income | 0.2 | 0.0 | 0.0 |
| Total income | 49.8 | 33.9 | 49.5 |
| Profit before exceptional items & tax | -1.3 | -6.3 | -3.8 |
| Profit before tax | -1.3 | -6.3 | -3.8 |
| Net profit | -1.7 | -4.8 | -2.2 |
| Operating margin | -2.6% | -18.6% | -7.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +0.20% |
|---|
Source
Read the filing ↗
BSE results filing, NSE: SSORGS. Figures extracted from the filing.
Oxygenta Pharmaceutical Ltd: key numbers
- Share price
- ₹49.61
- Market cap
- ₹183.5 Cr
- Revenue (annual)
- ₹113.0 Cr
- Net profit (annual)
- ₹-17.57 Cr
- P/E (TTM)
- -13.5×Sector 50.4×
- Promoter holding
- 56.54%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Oxygenta Pharmaceutical Ltd
All →
18:06 IST
BSE
Financial Results
Oxygenta Pharmaceutical Q1 FY27 Results: Net Loss of ₹2.1 Cr, Loss Narrows
Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹37 Cr (+145.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.
- Key figure
- Net loss ₹2.1 Cr